Cytokinetics (KK3A) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KK3A Analyst Ratings

Strong Buy

15 Buy

1 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KK3A Stock 12 Month Forecast

Average Price Target

€97.39

▲(58.51% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is €97.39 with a high forecast of €128.17 and a low forecast of €74.62. The average price target represents a 58.51% change from the last price of €61.44.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"€38","129":"€129","60.75":"€60.8","83.5":"€83.5","106.25":"€106.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":128.17496366,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€128.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.38956142933333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€97.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.62241035,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€74.62</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,60.75,83.5,106.25,129],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.44,66.57345874307693,71.70691748615384,76.84037622923077,81.97383497230769,87.10729371538461,92.24075245846154,97.37421120153846,102.50766994461539,107.64112868769232,112.77458743076923,117.90804617384616,123.04150491692309,{"y":128.17496366,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.44,64.20535087917949,66.97070175835897,69.73605263753846,72.50140351671794,75.26675439589744,78.03210527507692,80.79745615425641,83.56280703343589,86.32815791261538,89.09350879179486,91.85885967097435,94.62421055015383,{"y":97.38956142933333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,61.44,62.45403156538461,63.46806313076923,64.48209469615384,65.49612626153846,66.51015782692308,67.52418939230769,68.5382209576923,69.55225252307692,70.56628408846153,71.58031565384616,72.59434721923077,73.60837878461538,{"y":74.62241035,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.78,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.56,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.1,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.44,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€128.17

Average Price Target€97.39

Lowest Price Target€74.62

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leonid Timashev

RBC Capital

€98.33

Buy

60.04%

Upside

Reiterated

09/10/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (NASDAQ: REGN), Cytokinetics (NASDAQ: CYTK) and Biohaven Ltd. (NYSE: BHVN)

Srikripa Devarakonda

Truist Financial

€98.33

Buy

60.04%

Upside

Reiterated

09/01/26

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS)

Joseph Pantginis

H.C. Wainwright

€122.91

Buy

100.04%

Upside

Reiterated

08/31/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Cory Kasimov

Evercore ISI

€87.79

Buy

42.89%

Upside

Reiterated

08/31/26

Evercore ISI Remains a Buy on Cytokinetics (CYTK)

Jason Zemansky

Bank of America Securities

€74.62

Hold

21.46%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Becton Dickinson (NYSE: BDX)

Serge Belanger

Needham

€98.33

Buy

60.04%

Upside

Reiterated

08/28/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Choi

Goldman Sachs

€92.18

Buy

50.03%

Upside

Reiterated

08/28/26

Analysts Are Bullish on Top Healthcare Stocks: Resmed (RMD), Cytokinetics (CYTK)

Emily Field

Barclays

€96.57

Buy

57.18%

Upside

Reiterated

08/26/26

Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Summit Therapeutics (SMMT)

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

08/20/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Cytokinetics (NASDAQ: CYTK)

Yasmeen Rahimi

Piper Sandler

€93.94

Buy

52.89%

Upside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)

Jason Butler

Citizens JMP

€92.18→€96.57

Buy

57.18%

Upside

Reiterated

08/07/26

Cytokinetics price target raised to $110 from $105 at CitizensCytokinetics price target raised to $110 from $105 at Citizens

James Condulis

Stifel Nicolaus

€94.81

Buy

54.32%

Upside

Reiterated

08/07/26

Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)

Mayank Mamtani

B. Riley Securities

€128.17

Buy

108.62%

Upside

Reiterated

07/31/26

B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)

Maxwell Skor

Morgan Stanley

€90.42

Buy

47.18%

Upside

Assigned

07/23/26

Cytokinetics (CYTK) Receives a Buy from Morgan Stanley

Eric Joseph

Citi

€86.91

Buy

41.46%

Upside

Reiterated

07/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leonid Timashev

RBC Capital

€98.33

Buy

60.04%

Upside

Reiterated

09/10/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (NASDAQ: REGN), Cytokinetics (NASDAQ: CYTK) and Biohaven Ltd. (NYSE: BHVN)

Srikripa Devarakonda

Truist Financial

€98.33

Buy

60.04%

Upside

Reiterated

09/01/26

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS)

Joseph Pantginis

H.C. Wainwright

€122.91

Buy

100.04%

Upside

Reiterated

08/31/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Cory Kasimov

Evercore ISI

€87.79

Buy

42.89%

Upside

Reiterated

08/31/26

Evercore ISI Remains a Buy on Cytokinetics (CYTK)

Jason Zemansky

Bank of America Securities

€74.62

Hold

21.46%

Upside

Reiterated

08/31/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Becton Dickinson (NYSE: BDX)

Serge Belanger

Needham

€98.33

Buy

60.04%

Upside

Reiterated

08/28/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Paul Choi

Goldman Sachs

€92.18

Buy

50.03%

Upside

Reiterated

08/28/26

Analysts Are Bullish on Top Healthcare Stocks: Resmed (RMD), Cytokinetics (CYTK)

Emily Field

Barclays

€96.57

Buy

57.18%

Upside

Reiterated

08/26/26

Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Summit Therapeutics (SMMT)

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

08/20/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Cytokinetics (NASDAQ: CYTK)

Yasmeen Rahimi

Piper Sandler

€93.94

Buy

52.89%

Upside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)

Jason Butler

Citizens JMP

€92.18→€96.57

Buy

57.18%

Upside

Reiterated

08/07/26

Cytokinetics price target raised to $110 from $105 at CitizensCytokinetics price target raised to $110 from $105 at Citizens

James Condulis

Stifel Nicolaus

€94.81

Buy

54.32%

Upside

Reiterated

08/07/26

Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)

Mayank Mamtani

B. Riley Securities

€128.17

Buy

108.62%

Upside

Reiterated

07/31/26

B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)

Maxwell Skor

Morgan Stanley

€90.42

Buy

47.18%

Upside

Assigned

07/23/26

Cytokinetics (CYTK) Receives a Buy from Morgan Stanley

Eric Joseph

Citi

€86.91

Buy

41.46%

Upside

Reiterated

07/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

SLDBSolid Biosciences

AHCOAdaptHealth

KNSAKiniksa Pharmaceuticals

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months

Tessa RomeroJ.P. Morgan

Success Rate

16/25 ratings generated profit

Average Return

+24.03%

Copying Tessa Romero's trades and holding each position for 3 Months would result in 64.00% of your transactions generating a profit, with an average return of +24.03% per trade.

1 Year

Salim SyedMizuho Securities

Success Rate

37/53 ratings generated profit

Average Return

+33.46%

Copying Salim Syed's trades and holding each position for 1 Year would result in 69.81% of your transactions generating a profit, with an average return of +33.46% per trade.

2 Years

Jason ButlerCitizens JMP

Success Rate

23/28 ratings generated profit

Average Return

+30.69%

Copying Jason Butler's trades and holding each position for 2 Years would result in 82.14% of your transactions generating a profit, with an average return of +30.69% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KK3A Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KK3A has received 29 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. KK3A average Analyst price target in the past 3 months is 97.39.

Each month's total comprises the sum of three months' worth of ratings.

KK3A Financial Forecast

KK3A Earnings Forecast

Next quarter’s earnings estimate for KK3A is -€1.25 with a range of -€1.42 to -€0.95. The previous quarter’s EPS was -€1.29. KK3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.

KK3A Sales Forecast

Next quarter’s sales forecast for KK3A is €34.26M with a range of €23.73M to €44.14M. The previous quarter’s sales results were €24.59M. KK3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KK3A has Performed in-line its overall industry.

KK3A Stock Forecast FAQ

What is DE:KK3A’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 97.39.

What is DE:KK3A’s upside potential, based on the analysts’ average price target?

Cytokinetics has 58.51% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Cytokinetics a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy, which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.

What is Cytokinetics’s share price target?

The average share price target for Cytokinetics is 97.39. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €128.17 ,and the lowest forecast is €74.62. The average share price target represents 58.51% Increase from the current price of €61.44.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Cytokinetics?

To buy shares of DE:KK3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Cytokinetics (KK3A) Stock Forecast & Price Target

KK3A Analyst Ratings

KK3A Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

KK3A Analyst Recommendation Trends

KK3A Financial Forecast

KK3A Earnings Forecast

KK3A Sales Forecast

KK3A Stock Forecast FAQ

Detailed List of Analyst Forecasts